Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2/3 randomized, open-label, controlled, parallel-arm study of Ampligen in patients with advanced or metastatic late-stage pancreatic cancer

X
Trial Profile

A phase 2/3 randomized, open-label, controlled, parallel-arm study of Ampligen in patients with advanced or metastatic late-stage pancreatic cancer

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 22 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors AIM ImmunoTech
  • Most Recent Events

    • 19 Oct 2021 According to an AIM ImmunoTech media release, the company has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the USA Food and Drug Administration (FDA) for this study.
    • 04 Oct 2021 According to an AIM ImmunoTech media release, Prof. Kelsey Klute is the study's principal investigator in the United States.
    • 04 Oct 2021 According to an AIM ImmunoTech media release, the company has finalized the protocol for a planned Phase 2 study and the company expects to submit both an Investigational New Drug application (IND) and an application for Fast Track status with the U.S. Food and Drug Administration (FDA) no later than October 18, 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top